MedTrace Logo

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06307795 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2026-04-17

No results posted yet for this study

Summary

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

ANS014004

Varying doses of ANS014004

Sponsors & Collaborators

  • Avistone Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Medical Director Clinical Science · Beijing Avistone Biotechnology Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-24
Primary Completion
2027-04-30
Completion
2027-10-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06307795 on ClinicalTrials.gov